Top Stocks To Watch Right Now

Angel Commodities’ report on Gold

On Wednesday, spot gold prices rose 0.3 percent to close at $ 1299.3 per ounce as weakness in the DX ahed of FOMC state men t buoyed the yellow metal. Earlier this week, the dollar strengthened following a positive U.S. – North Korea summit, with markets now waiting for a likely interest rate hike by the U.S. Federal Reserve. The dollar hit a three – week high against the yen on Tuesday and Asian shares gained as U.S. President Donald Trump and North Korean leader Kim Jong Un signed a “comprehensive” deal at a historic summit aimed at the denuclearisation of the Korean peninsula. MCX gold prices declined marginally to close at Rs.31143/10gms on Wednesday.

Outlook
Gold prices are likely to trade lower after the widely expected rate hike announcement by the Federal Reserve amidst strong inflation and jobs numbers. On the MCX, gold prices are expected to trade lower today, international markets are trading marginally lower at $ 1298.3 per ounce.

For all commodities report, click here

Top Stocks To Watch Right Now: RXI Pharmaceuticals Corporation(RXII)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    MoSys, Inc. (NASDAQ: MOSY) shares rose 44.7 percent to $2.20 in pre-market trading after the company reported better-than-expected Q1 results and issued strong Q2 forecast.
    The Trade Desk, Inc. (NASDAQ: TTD) rose 23.2 percent to $65.01 in pre-market trading after the company reported upbeat results for its first quarter. The company also issued strong second-quarter and FY18 sales guidance.
    Immersion Corporation (NASDAQ: IMMR) rose 17 percent to $13.55 in pre-market trading after reporting upbeat Q1 results.
    Akcea Therapeutics, Inc. (NASDAQ: AKCA) rose 13.8 percent to $23.50 in pre-market trading after the company disclosed that the FDA Advisory Committee voted in favor of WAYLIVRA for the treatment of familial chylomicronemia syndrome.
    RXi Pharmaceuticals Corporation (NASDAQ: RXII) rose 9.4 percent to $2.45 in pre-market trading after the company disclosed a collaboration with Iovance Biotherapeutics.
    ViewRay, Inc. (NASDAQ: VRAY) rose 13.7 percent to $8.80 in pre-market trading after reporting upbeat quarterly earnings.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 5.6 percent to $32.00 in pre-market trading after falling 2.26 percent on Thursday.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 5.6 percent to $9.30 in pre-market trading after reporting Q3 results.
    Aflac Incorporated (NYSE: AFL) rose 4.7 percent to $47.50 in pre-market trading.
    Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 4.2 percent to $2.24 in pre-market trading following Q1 earnings.
    Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) shares rose 3.7 percent to $11.00 in pre-market trading after the company reported Q1 earnings.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Lisa Levin] Gainers
    ARMO BioSciences, Inc. (NASDAQ: ARMO) shares rose 67.5 percent to $49.96 in pre-market trading after Eli Lilly and Company (NYSE: LLY) announced plans to acquire ARMO BioSciences for $50 per share.
    Turtle Beach Corporation (NASDAQ: HEAR) rose 62.8 percent to $11.30 in pre-market trading after the company reported Q1 results and raised its FY18 outlook.
    vTv Therapeutics Inc. (NASDAQ: VTVT) rose 23.4 percent to $2.11 in pre-market trading following announcement that the company will pre-specify new subgroup with the FDA and report Phase 3 Part B results in June.
    Resonant Inc. (NASDAQ: RESN) rose 19.1 percent to $5.00 in pre-market trading after reporting Q1 results.
    RXi Pharmaceuticals Corporation (NASDAQ: RXII) rose 17.7 percent to $2.39 in pre-market trading following Q1 results.
    Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 15.2 percent to $2.20 in pre-market trading after French company Total announced plans to acquire 25 percent stake in Clean Energy Fuels for $83.4 million.
    Everspin Technologies, Inc. (NASDAQ: MRAM) rose 14.6 percent to $8.50 in pre-market trading after the company reported strong results for its first quarter.
    Carvana Co. (NYSE: CVNA) shares rose 11 percent to $27.50 in pre-market trading after reporting upbeat Q1 sales.
    Sunrun Inc. (NASDAQ: RUN) rose 8.9 percent to $10.70 in pre-market trading following upbeat quarterly earnings.
    MediciNova, Inc. (NASDAQ: MNOV) rose 8.1 percent to $11.35 in pre-market trading after the company announced opening of Investigational New Drug Application for MN-166 (ibudilast) in glioblastoma.
    New Gold Inc. (NYSE: NGD) shares rose 7.7 percent to $2.65 in pre-market trading after the company reported that its President and CEO Hannes Portmann left the company. The company named Raymond Threlkeld as successor.
    Otter Tail Corporation (NASDAQ: OTTR) shares rose 7.4 percent to $46.60 in the pre-market trading session.
    Himax Technologies, Inc. (NASDAQ: HIMX) shares rose
  • [By Shane Hupp]

    These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

    Get RXi Pharmaceuticals alerts:

    New Research Study on Connective Tissue Growth Factor Market 2018 to 2025 (morningoutlook.com) Hypoxia Inducible Factor 1 Alpha Market Pipeline Therapeutics H1, 2018 Product Description, Mechanism of Action … (exclusiveherald.com) Human Papillomavirus Associated Diseases Market Pipeline Therapeutics 2018 Drug Description, Target Finding, and … (thefreenewsman.com) Warts Market Therapeutic Pipeline H1, Drugs, Diagnostics, Vaccines and Preventive Technologies (newspublicist.com) Brokerages Anticipate RXi Pharmaceuticals Corp (RXII) to Post -$0.56 Earnings Per Share (americanbankingnews.com)

    Shares of RXi Pharmaceuticals traded down $0.01, hitting $2.24, on Tuesday, MarketBeat Ratings reports. 55,400 shares of the stock were exchanged, compared to its average volume of 275,015. The company has a market capitalization of $9.96 million, a price-to-earnings ratio of -0.53 and a beta of 1.15. RXi Pharmaceuticals has a one year low of $1.90 and a one year high of $7.70.

  • [By Shane Hupp]

    These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

    Get RXi Pharmaceuticals alerts:

    Intercellular Adhesion Molecule 1 Market Pipeline Review H1 Products in Clinical Stage, Methodology, therapeutic … (talkinvestor.com) Hypoxia Inducible Factor 1 Alpha Market Research Report H1: Drug Profile, Top Industry Intelligence and Therapeutic … (thestockanalysis.com) Connective Tissue Growth Factor Market Opportunities, Demands, Size, Share, Trends, Industry Sales Area and Its … (trueindustrynews.com) Global Connective Tissue Growth Factor Market 2018 Manufacturing Analysis and Development Forecast 2025 (trueindustrynews.com) Zacks: Analysts Expect RXi Pharmaceuticals Corp (RXII) to Announce -$0.56 EPS (americanbankingnews.com)

    Shares of RXi Pharmaceuticals stock traded down $0.04 on Tuesday, hitting $1.92. The company had a trading volume of 27,600 shares, compared to its average volume of 258,173. The stock has a market capitalization of $8.21 million, a PE ratio of -0.46 and a beta of 1.20. RXi Pharmaceuticals has a 52 week low of $1.90 and a 52 week high of $7.70.

Top Stocks To Watch Right Now: Equinix Inc.(EQIX)

Advisors’ Opinion:

  • [By Max Byerly]

    Front Row Advisors LLC increased its position in Equinix Inc (NASDAQ:EQIX) by 7.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,175 shares of the financial services provider’s stock after buying an additional 150 shares during the quarter. Front Row Advisors LLC’s holdings in Equinix were worth $909,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Lee Jackson]

    This is one of the larger cap companies in the data center arena and a top play for more conservative accounts. Equinix Inc. (NASDAQ: EQIX) provides data center services to protect and connect the information assets for the enterprises, financial services companies, and content and network providers primarily in the Americas, Europe, the Middle East, Africa and the Asia-Pacific.

  • [By Stephan Byrd]

    Credit Suisse Group set a $525.00 price objective on Equinix (NASDAQ:EQIX) in a research report report published on Friday. The firm currently has a buy rating on the financial services provider’s stock.

  • [By Stephan Byrd]

    US Bancorp DE boosted its holdings in Equinix (NASDAQ:EQIX) by 12.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,159 shares of the financial services provider’s stock after purchasing an additional 920 shares during the quarter. US Bancorp DE’s holdings in Equinix were worth $3,411,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Equinix (EQIX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Matthew Frankel]

    Equinix (NASDAQ:EQIX) is the largest operator of data centers in the world, with more than 9,800 companies utilizing its properties. The company provides the facility, power, security, and cooling equipment for its customers, and they supply their own servers and networking equipment.

Top Stocks To Watch Right Now: Western Copper and Gold Corporation(WRN)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Western Copper (NYSEAMERICAN:WRN) (TSE:WRN) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 367,976 shares, an increase of 17.9% from the May 31st total of 312,021 shares. Based on an average daily trading volume, of 131,386 shares, the short-interest ratio is currently 2.8 days.

Top Stocks To Watch Right Now: T2 Biosystems, Inc.(TTOO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of T2 Biosystems, Inc. (NASDAQ: TTOO) were down 12 percent to $7.80 after the health care company that targets unmet needs received clearance from the FDA. The company said the FDA granted a market clearance for its T2Bacteria Panel for the direct detection of bacterial species in human whole blood specimens from patients with suspected bloodstream infections.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Co-Diagnostics, Inc. (NASDAQ: CODX) fell 11.6 percent to $3.13 in pre-market trading after surging 118.52 percent on Tuesday.
    Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) shares fell 6.5 percent to $2.60 in pre-market trading after rising 1.09 percent on Tuesday.
    T2 Biosystems, Inc. (NASDAQ: TTOO) fell 6 percent to $7.58 in pre-market trading after dropping 9.13 percent on Tuesday.
    Era Group Inc. (NYSE: ERA) fell 4.8 percent to $12.30 in the pre-market trading session.
    DSW Inc. (NYSE: DSW) shares fell 4.1 percent to $25.00 in pre-market trading after reporting Q1 results.
    ZTO Express (Cayman) Inc. (NYSE: ZTO) shares fell 2.7 percent to $20.25 in pre-market trading after rising 7.88 percent on Tuesday.
    Daktronics, Inc. (NASDAQ: DAKT) fell 2.5 percent to $9.81 in pre-market trading. Daktronics is expected to release quarterly earnings today.
    AngloGold Ashanti Limited (NYSE: AU) fell 2.2 percent to $8.28 in pre-market trading

  • [By Logan Wallace]

    HC Wainwright reiterated their buy rating on shares of T2 Biosystems (NASDAQ:TTOO) in a report issued on Thursday morning. The firm currently has a $14.00 target price on the medical equipment provider’s stock.

  • [By Max Byerly]

    T2 Biosystems (NASDAQ:TTOO) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on T2 Biosystems (TTOO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Maxx Chatsko]

    Shares of diagnostic test and device developer T2 Biosystems (NASDAQ:TTOO) jumped as much as 16.1% today after a volatile week. The good news is that the company recently announced that the U.S. Food and Drug Administration cleared its T2Bacteria Panel, which is aimed at detecting the presence of sepsis-causing pathogens in blood samples.

Leave a Reply

Your email address will not be published. Required fields are marked *